Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics, Inc (RNTX)
NASDAQ:RNTX
RNTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $4.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)48.44K
Market Cap
$27.19M
Enterprise Value$76.37M
Total Cash (Recent Filing)$7.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Nov 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,046,122
10 Day Avg. Volume80,340
30 Day Avg. Volume48,441
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap2.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-13.56
Forecast
1Y Price Target
$8.00Price Target Upside577.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics, Inc’s price range in the past 12 months?
Rein Therapeutics, Inc lowest stock price was $1.04 and its highest was $4.40 in the past 12 months.
What is Rein Therapeutics, Inc’s market cap?
Rein Therapeutics, Inc’s market cap is $27.19M.
When is Rein Therapeutics, Inc’s upcoming earnings report date?
Rein Therapeutics, Inc’s upcoming earnings report date is Nov 14, 2025 which is in 92 days.
How were Rein Therapeutics, Inc’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics, Inc overvalued?
According to Wall Street analysts Rein Therapeutics, Inc’s price is currently Undervalued.
Does Rein Therapeutics, Inc pay dividends?
Rein Therapeutics, Inc does not currently pay dividends.
What is Rein Therapeutics, Inc’s EPS estimate?
Rein Therapeutics, Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics, Inc have?
Rein Therapeutics, Inc has 23,046,122 shares outstanding.
What happened to Rein Therapeutics, Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics, Inc?
Currently, no hedge funds are holding shares in RNTX
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (577.97% Upside)
$8.00 (577.97% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.81%
12-Months-Change
Fundamentals
Return on Equity
-86.78%
Trailing 12-Months
Asset Growth
-41.90%
Trailing 12-Months
Company Description
Rein Therapeutics, Inc
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
Technical Analysis
Alterity Therapeutics
―
Kala Pharmaceuticals
―
Kezar Life Sciences
―
Vicarious Surgical
―
Connect Biopharma Holdings
―
Ownership Overview
2.08% Insiders
3.99% Mutual Funds
0.61% Other Institutional Investors
89.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---